4.4 Review

From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease

期刊

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
卷 8, 期 3, 页码 143-159

出版社

SAGE PUBLICATIONS LTD
DOI: 10.1177/1756283X15576462

关键词

Crohn's Disease; Inflammatory Bowel Disease; biologics; anti-TNF

资金

  1. Abbvie
  2. UCB
  3. Janssen
  4. Takeda
  5. Salix
  6. Prometheus
  7. Amgen
  8. Bristol-Meyers Squibb

向作者/读者索取更多资源

Crohn's disease (CD) is a debilitating, systemic inflammatory disorder with both gastrointestinal and extraintestinal manifestations. Its existence predates modern medicine, but its precise etiology remains incompletely understood. Most authorities suggest a multifactorial pathogenesis owing to a mixture of genetic disorders, immunologic dysregulation, microbiota disequilibrium and environmental influences. Of these factors, the overactive immunologic response seen in CD appears to be the most promising target of medical therapy. Biological agents comprise a relatively new class of drugs that can induce and maintain remission in moderate to severe CD, as well as in ulcerative colitis. This review will provide an overview of CD, its history, clinical features, pathophysiology, and treatment options focusing on current and future biological agents with an emphasis on drug development, dosage and administration.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据